SecBot SecBot
Insider Cluster (2 insiders) ·Filed May 7, 2026

RCKT

ROCKET PHARMACEUTICALS, INC.
NEUTRAL
Impact 3/10
Horizonweeks Processed6mo ago
Insider cluster: 2 insiders, $78K total
Actionable Insight • Neutral

The insider sales are too small to signal material bearishness. Monitor for any further insider selling or clinical updates on Danon disease, which is the next major catalyst. The stock's low price near $3.60 may attract speculative interest ahead of H2 2026 data.

DirectionNeutral
Confidencemedium
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$3.25
T+0 close · May 14, 2026 · via day close
Latest settled
+7.69%
T+60 · $3.50
Vs SPY
+3.18%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 15 $3.25entry
  2. T+1 · 6mo ago −5.54%α −5.48% · $3.07
  3. T+5 · 6mo ago −8.92%α −9.89% · $2.96
  4. T+20 · 5mo ago −12.00%α −14.12% · $2.86
  5. T+60 · 3mo ago +7.69%α +3.18% · $3.50

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Rocket Pharmaceuticals CEO Gaurav Shah sold $10K worth of shares and another insider sold $68K, totaling $78K in open-market sales over a 7-day window. This follows the Q1 earnings report showing a narrowed net loss and the $180M PRV monetization, but the stock trades near $3.60 with a $393M market cap. The insider sales are modest (0.02% of market cap) and likely driven by routine portfolio management rather than a bearish signal, especially given the recent positive catalyst.

Key Financial Metrics

Direction
selling
Total Value
$78.0K
Insiders
2

Key Facts

  • CEO Gaurav Shah sold 2,728 shares at $3.606 for ~$10K on May 13, 2026.
  • Sarbani Chaudhuri sold 17,600 shares at $3.84 for ~$68K on May 7, 2026.
  • Total insider sales of $78K represent ~0.02% of RCKT's $393M market cap.
  • Q1 2026 net loss improved to -$47.6M from -$61.3M YoY; KRESLADI approved and PRV monetized for $180M.
  • Cash runway extended into Q2 2028; Danon disease Phase 2 update expected H2 2026.

Financial Impact

Insider sales of $78K are trivial relative to $393M market cap (0.02%).

dilutioninsider ownership

Risk Factors

  • Further insider selling could erode confidence if it accelerates.
  • Danon disease trial failure would be a major setback.
  • Cash burn remains high despite extended runway.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
55% bullish (20 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-RCKT-1778790001885

US Market Status

Market Closed · Opens in 6h 42m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 14, 2026